Ajay K. Gopal, MD
Department of Medicine
Division of Oncology
Seattle Cancer Care Alliance
825 Eastlake Ave E, G3-200
Seattle, WA 98109-1023
Sonia Priscila Y. Bill
Specialty / Expertise
Lymphoma/Chronic Lymphocytic Leukemia (CLL)
Developing novel targeted therapies for lymphomas with particular emphasis on radioimmunotherapy-based transplant conditioning regimens, low toxicity Proapoptotic agents for indolent lymphomas, and safe curative regimens for older adults with lymphoma.
Current Research Projects
1390, A Retrospective Study
Funding Source: Non clinical trial
The major goal of this project is a retrospective evaluation of patients treated with high-dose therapy followed by autologous or allogeneic transplantation.
Funding Source: Calistoga Pharmaceuticals, Inc.
The major goal is a phase II study to access the efficacy and safety of CAL-101 in patients with indolent B-Cell Non-Hodgkin lymphoma refractory to Rituximab and alkylating agents.
7176, A Phase II Study
Funding Source: UW - Cephalon, Inc
The major goal is a phase II study of Bendamustine (B), Dexamethasone (D), and GCSF (G) for peripheral blood hematopoietic stem cell mobilization.
PSOC 2502 A Phase I trial
Funding Source: Cephalon, Inc.
The major goal is a phase I trial of Bendamustine/Treanda (T), Rituximab (R), Etoposide (E), and Carboplatin (C) for patients with relapsed or refractory lymphoid malignancies and select untreated lymphomas (TREC).
Funding Source: Seattle Genetics, Inc.
The major goal is an open-label clinical pharmacology study of brentuximab vedotin (SGN-35) in patients with CD30-positive hematologic malignancies: CYP3A4 drug-drug interactions, excretion, and special populations.
UW09044 (SGN35-006 Extension Study)
Funding Source: Seattle Genetics, Inc.
The major goal of this study is the treatment with SGN-35 in patients with CD30-positive hematologic malignancies who have previously participated in an SGN-35 study.
Dr. Gopal received his BS from Duke University, Durham, NC, and his MD from Emory School of Medicine, Atlanta, GA. He completed his Internal Medicine Residency at Duke University Medical Center, Durham, NC, where he was selected as Assistant Chief Resident. He then completed his Medical Oncology Fellowship at the University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA in 1997.
Gopal AK, Guthrie K, Rajendran J, Pagel JM, Oliviera G, Matesan M, Maloney DG, Storb RF, Press OW. Y-90-Ibritumomab Tiuxetan, Fludarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for patients with persistent High-Risk B-Cell Lymphoma. (in press) Blood.
Ram R, Gooley TA, Maloney DG, Press OW, Pagel JM, Petersdorf SH, Shustov AR, Flowers MED, O’Donnell P, Sandmaier BM, Storb RF and Gopal AK. Histology and Time to progression predict survival for lymphoma recurring after reduced intensity conditioning and allogeneic hematopoietic cell transplantation. (in press) Biol Blood Marrow Transplantation.
Shustov AR, Cherian S, Shaw A, Lupinacci T, Maloney D, Holmberg L and Gopal AK. In-vivo purging of the circulating clonal T-cells with Alemtuzumab prior to autologous peripheral blood hematopoietic cell mobilization and transplantation. (in press) Br J Haematol.
Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, Estey EH, Salter AI, Lansverk E, Chien JW, Gopal AK, Appelbaum FR, Pagel JM. Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. J Clin Oncol. 2011 Jan 31. [Epub ahead of print] PMID: 21282535
Ivey RG, Moore HD, Voytovich UJ, Thienes CP, Lorentzen TD, Pogosova-Agadjanyan EL, Frayo S, Izaguirre VK, Lundberg SJ, Hedin L, Badiozamani KR, Hoofnagle AN, Stirewalt DL, Wang P, Georges GE, Gopal AK, Paulovich AG. Blood-Based Detection of Radiation Exposure in Humans Based on Novel Phospho-Smc1 ELISA. Radiat Res. 2011 175(3):266-281. PMID: 21171809
Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T, Lin Y, Fisher DR, Gopal AK, Green DJ, Press OW. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood. 2010 Nov 18;116(20):4231-9. Epub 2010 Aug 11. PMID: 20702781 PMCID: PMC2993626
Gopal AK, Press OW, Shustov A, Petersdorf S, Gooley T, Daniels J, Garrison M, Gierset G, Lonergan M, Murphy A, Smith J, Pagel JM. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma. 2010 Aug;51(8):1523-9. PMID:20578815 PMCID: PMC3018339
Vaughn JE, Gopal AK. Relapsed mantle cell lymphoma presenting as "Sister Mary Joseph nodule”. Case Report Med. 2010;2010:708348. Epub 2010 Apr 8.
Shenoi J, Gopal AK, Press OW, Pagel JM. Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation. Curr Opin Oncol. 2010 Mar;22(2):143-9. PMID: 20019612
Pagel JM, Gooley TA, Fisher DR, Wilson WA, Gopal AK, Press OW and Appelbaum FR. Allogeneic hematopoietic cell transplantation after conditioning with I131-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood. 2009 Dec 24;114(27):5444-53. Epub 2009 Sep 28.
Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A, Hamlin DK, Wilbur DS, Fisher DR, Rajendran JG, Gopal AK, Park SI, Press OW. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood. 2009 Aug 6;114(6):1226-35. Epub 2009 Jun 10. PMCID: PMC2723017
Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, Bosly A, Pinter-Brown L, Kennedy D, Sievers EL, Gopal AK. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009 Jul;146(2):171-9. Epub 2009 May 19.
Gopal AK, Pagel JM, Fromm JR, Wilbur S and Press OW. I-131-Anti-CD45 Radioimmunotherapy Effectively Targets and Treats T-Cell Non-Hodgkin Lymphoma. 2009 Blood. Jun 4;113(23):5905-10. PMCID: PMC2700326
Pagel JM, Orgun N, Hamlin DK, Wilbur DS, Gooley TA, Gopal AK, Park SI, Green DJ, Lin Y, Press OW. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood. 2009 May 14;113(20):4903-13. Epub 2009 Jan 5. PMCID: PMC2686140
McCarthy J, Gopal AK. Successful use of full-dose dexamethasone, high-dose cytarabine, and cisplatin as part of initial therapy in non-hodgkin and hodgkin lymphoma with severe hepatic dysfunction. Clin Lymphoma Myeloma. 2009 Apr;9(2):167-70.
Pagel JM, Matthews DC, Kenoyer A, Hamlin DK, Wilbur DS, Fisher DR, Gopal AK, Lin Y, Saganic L, Appelbaum FR, Press OW. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. Cancer Res. 2009 Jan 1;69(1):185-92. PMCID: PMC2613544
Zaucha R, Gooley T, Holmberg L, Gopal AK, Press O, Maloney D, Bensinger WI. High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma. 2008 Oct;49(10):1899-906.
Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR, Press OW. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008 Sep 15;112(6):2261-71. Epub 2008 May 28. PMCID: PMC2532803
Gopal AK, Metcalfe TL, Gooley TA, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Maloney DG, Press OW. High-Dose therapy and autologous stem cell transplantation for chemoresistant hodgkin lymphoma: The Seattle experience. Cancer 2008 Sep 15;113(6):1344-50. PMCID: PMC2700660
Gopal AK, Press OW, Wilbur DS, Maloney DG, Pagel JM. Rituximab blocks binding radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45-Ab. Blood 2008 Aug 1;112(3):830-5. PMCID: PMC2481554.
Last updated: May 2011